Colorectal cancer (CRC), and breast, ovarian, pancreatic and prostate cancers are generally
considered as low immune-reactive cancers that represent either limited infiltration of …

Hypoxia is a known feature of solid tumors and a critical promoter of tumor hallmarks.
Hypoxia influences tumor immunity in a way favoring immune evasion and resistance …

Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease refractory to all
targeted and immune therapies. However, our understanding of PDAC microenvironment …

Pancreatic ductal adenocarcinoma (PDAC) interacts closely with the tumor
microenvironment (TME). The TME is remodeled by crosstalk between pancreatic cancer …

Pancreatic cancer (PC) remains one of the most lethal malignancies across the world, which
is due to delayed diagnosis and resistance to current therapies. The interactions between …

Simple Summary Tumors from pancreatic cancer contain many types of cells (such as
immune cells and fibroblasts) in addition to the cancer cells. Using targeted drugs to disrupt …

Natural killer (NK) cells are lymphoid cells of innate immunity that take important roles in
immune surveillance. NK cells are considered as a bridge between innate and adaptive …

Advanced pancreatic cancer patients have a dismal prognosis despite advances in
integrative therapy. The field of tumor immunology has witnessed significant advancements …

Abstract Introduction 5-fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) is
promising in treating patients with pancreatic ductal adenocarcinoma. However, many …

Introduction Pancreatic cancer is associated with poor prognosis, and limited treatment
options are available for the majority of patients. Natural killer (NK) cells in combination with …